Previous 10 | Next 10 |
The clinical study, COVALENT-112, has initiated enrollment of adults living with type 1 diabetes in the US and Canada. Eligible patients include those who have been diagnosed with type 1 diabetes for up to 15 years. Data from the Phase II study are expected in 2024. REDWOOD CITY, ...
REDWOOD CITY, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically define...
2023-12-13 02:51:56 ET Summary Biomea Fusion's BMF-219 shows potential in diabetes but lags in efficacy compared to competitors. Increased R&D expenses led to higher operating losses and share dilution, but the company maintains a strong current ratio. Market sentiment is ...
2023-12-11 12:51:49 ET Gainers: Jet.AI ( JTAI ) +70% . Boqii Holding Limited ( BQ ) +34% . Marker Therapeutics ( MRKR ) +34% . Morphosys AG ( MOR ) +25% . G1 Therapeutics ( GTHX ) +24% . Innoviz Technologies Ltd ( INVZ ) ...
2023-12-11 10:00:03 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom For further details see: Veru, Kodiak S...
BMF-219 demonstrated early signs of clinical activity and ability to achieve durable and sustained complete responses (CRs) with minimal residual disease negativity (MRD-neg) in acute myeloid leukemia (AML) patients Pharmacodynamic data further supports the mechanism of action of BMF-219 as a...
2023-12-11 08:27:31 ET Losers: Cogent Biosciences ( COGT ) -31% . announces positive data from ongoing phase 2 APEX trial evaluating Bezuclastinib in patients . Purple Biotech Ltd ( PPBT ) -16% . Sphere 3D Corp ( ANY ) -14% . FLJ Group Ltd ( F...
At Week 26, 22 weeks after the last dose of BMF-219, the 200 mg cohorts increased the percentage of patients to approximately 40% with durable HbA1c reduction of 1% or more as compared to the 100 mg cohorts which reported earlier as 20%. To date, the dose escalation portion has shown after on...
2023-12-08 16:43:19 ET Gainers: IGM Biosciences, Inc. ( IGMS ) +9% . EF Hutton Acquisition Corporation I ( EFHT ) +6% . Biomea Fusion ( BMEA ) +5% . Larimar Therapeutics ( LRMR ) +2% . First Solar ( FSLR ) +1% . Losers: L...
2023-12-08 13:13:33 ET More on Biomea Fusion Navigating Biomea Fusion's Labyrinth: From Blood To Beta Cells Biomea stock tumbles in wake of Phase 2 data for diabetes drug Biomea Fusion spikes after mid-stage data for diabetes candidate Seeking Alpha’s ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-18 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-18 04:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, NY / ACCESSWIRE / June 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biomea Fusion, Inc. ("Biomea" or "the Company") (NASDAQ:BMEA). Investors who purchased Biomea securities are encouraged to obtain additional information...